|1.||Davì, Giovanni: 5 articles (08/2014 - 10/2002)|
|2.||Ciabattoni, Giovanni: 4 articles (06/2007 - 10/2002)|
|3.||Patrono, Carlo: 4 articles (12/2006 - 10/2002)|
|4.||Basili, Stefania: 3 articles (12/2006 - 10/2002)|
|5.||Carnevale, Roberto: 2 articles (10/2015 - 09/2015)|
|6.||Violi, Francesco: 2 articles (10/2015 - 09/2015)|
|7.||Pignatelli, Pasquale: 2 articles (10/2015 - 09/2015)|
|8.||Bucci, Tommaso: 2 articles (10/2015 - 09/2015)|
|9.||Farcomeni, Alessio: 2 articles (10/2015 - 09/2015)|
|10.||Bartimoccia, Simona: 2 articles (10/2015 - 09/2015)|
|1.||Coronary Artery Disease (Coronary Atherosclerosis)
12/18/2015 - "To elucidate the correlation between urinary 11-dehydro-thromboxane B2 (11dhTxB2) and clinical efficacy of aspirin treatment in patients with type 2 diabete and coronary artery disease (CAD). "
12/18/2015 - "[Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabete and coronary artery disease]."
10/15/2015 - "The aim of our study was to compare between two established methods of aspirin response, urinary 11-dehydrothromboxane B2 (11dhTXB2) and platelet Light Transmission Aggregometry (LTA) assays in elderly Chinese patients with coronary artery disease (CAD), and to investigate the clinical significance of both methods in predicting cardiovascular events. "
10/15/2015 - "Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease."
06/01/2011 - "Platelet function tests with arachidonic acid (ARA) and urinary 11-dehydro-thromboxane B2 (11-DH-TXB2) concentrations were performed in 262 patients with unstable coronary artery disease who had not been taking aspirin before admission. "
08/01/1992 - "Our findings suggest that urinary 11-dehydro-thromboxane B2 may have an important role in the diagnosis and treatment of arteriogenic impotence."
08/01/1992 - "The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence."
08/01/1992 - "The mean urinary 11-dehydro-thromboxane B2 level of 3 patients with arteriogenic impotence was significantly greater than that of the 57 control volunteers: 2.66 +/- 0.65 versus 1.74 +/- 0.56 (plus or minus standard deviation) ng./mg. creatinine (p = 0.008). "
08/01/1992 - "For the 13 patients with arteriogenic impotence (group 3) we compared the urinary 11-dehydro-thromboxane B2 and prostaglandin F1 alpha levels before and after intracavernous injection of prostaglandin E1 by using a paired t test. "
08/01/1992 - "The 11-dehydro-thromboxane B2 concentration in the urine was 1.83 +/- 0.58, 2.54 +/- 1.12 and 1.91 +/- 0.73 ng./mg. creatinine in the 47 normal control volunteers, 20 patients with arteriogenic impotence and 29 with arteriogenic impotence plus intracavernous injection of 20 micrograms prostaglandin E1, respectively. "
|4.||Nephrotic Syndrome (Syndrome, Nephrotic)
01/01/1997 - "In order to examine the intracellular thromboxane A2 (TXA2) signal transduction system in platelets of patients with nephrotic syndrome, we measured the levels of TXA2 metabolites in urine and blood and platelet calcium ion level as a result of STA2, an analog of STA2 (9,11-dimethylmethano-11,12-methano-TXA2) stimulation, and obtained the following results: (1) In pediatric patients with nephrotic syndrome, urinary thromboxane B2 (TXB2) and 11-dehydro-TXB2 excretion were signficantly higher in the onset and relapse groups compared to the remission and control groups. "
|1.||Aspirin (Acetylsalicylic Acid)
|3.||Thromboxane A2 (A2, Thromboxane)
|1.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)